Effect of coating thickness of iron oxide nanoparticles on their relaxivity in the MRI

Document Type: Original Article


1 Biomolecular Imaging Analysis Group, Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Science, Tehran, Iran

3 Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran

4 Micromod Partikeltechnologie GmbH, Friedrich-Barnewitz-Str. 4, D-18119 Rostock, Germany


Objective(s):Iron oxide nanoparticles have found prevalent applications in various fields including drug delivery, cell separation and as contrast agents. Super paramagnetic iron oxide (SPIO) nanoparticles allow researchers and clinicians to enhance the tissue contrast of an area of interest by increasing the relaxation rate of water. In this study, we evaluate the dependency of hydrodynamic size of iron oxide nanoparticles coated with Polyethylene  glycol (PEG) on their relativities with 3 Tesla clinical MRI.
Materials and Methods: We used three groups of nanoparticles with nominal sizes 20, 50 and 100 nm with a core size of 8.86 nm, 8.69 nm and 10.4 nm that they were covered with PEG 300 and 600 Da. A clinical magnetic resonance scanner determines the T1 and T2 relaxation times for various concentrations of PEG-coated nanoparticles.

The size measurement by photon correlation spectroscopy showed the hydrodynamic sizes of MNPs with nominal 20, 50 and 100 nm with 70, 82 and 116 nm for particles with PEG 600 coating and 74, 93 and 100 nm for  particles with PEG 300 coating, respectively. We foud that the relaxivity decreased with increasing overall particle size (via coating thickness). Magnetic resonance imaging showed that by increasing the size of the nanoparticles, r2/r1 increases linearly.
Conclusion: According to the data obtained from this study it can be concluded that increments in coating thickness have more influence on relaxivities compared to the changes in core size of magnetic nanoparticles.


1. Gamarra L, Pontuschka WM, Amaro E, Costa-Filho A, Brito G, Vieira E, et al. Kinetics of elimination and distribution in blood and liver of biocompatible ferrofluids based on Fe 3 O 4 nanoparticles: An EPR and XRF study. Mater Sci Eng C 2008;28:519-25.

2. Shanehsazzadeh S, Gruettner C, Lahooti A, Mahmoudi M, Allen BJ, Ghavami M, et al. Monoclonal antibody conjugated magnetic nanoparticles could target MUC‐1‐positive cells in vitro but not in vivo. Contrast Media Mol Imaging 2015; 10:225–36.

3.   Zhao X, Zhao H, Chen Z, Lan M. Ultrasmall superparamagnetic iron oxide nanoparticles for magnetic resonance imaging contrast agent. J Nanosci Nanotechnol 2014; 14:210-20.

4.   Shanehsazzadeh S, Oghabian MA, Allen BJ, Amanlou M, Masoudi A, Daha FJ. Evaluating the effect of ultrasmall superparamagnetic iron oxide nanoparticles for a long-term magnetic cell labeling. J Med Phys 2013; 38:34.

5.   Shanehsazzadeh S, Oghabian MA, Lahooti A, Abdollahi M, Haeri SA, Amanlou M, et al. Estimated background doses of [67Ga]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancers. Nucl Med Commun  2013; 34:915-25.

6.   Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 2011; 63:24-46.

7.   Bagheri-abassi F, Alavi H, Mohammadipour A, Motejaded F. Ebrahimzadeh-bideskan, A., The effect of silver nanoparticles on apoptosis and dark neuron production in rat hippocampus. Iran J Basic Med Sci 2015,18, 644-648.

8. Mayelifar K, Taheri AR, Rajabi O, Sazgarnia A. Ultraviolet B efficacy in improving antileishmanial effects of silver nanoparticles. Iran J Basic Med Sci 2015, 18, 677-683.

9. Lind K, Kresse M, Debus NP, Müller RH. A novel formulation for superparamagnetic iron oxide (SPIO) particles enhancing MR lymphography: comparison of physicochemical properties and the in vivo behaviour. J Drug Target 2002;10:221-30.

10. Mahmoudi M, Simchi A, Imani M, Hafeli UO. Superparamagnetic iron oxide nanoparticles with rigid cross-linked polyethylene glycol fumarate coating for application in imaging and drug delivery. J Phys Chem C 2009; 113:8124-31.

11. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2:214-21.

12. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318.

13. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004;5:981-6.

14. Ni F, Jiang L, Yang R, Chen Z, Qi X, Wang J. Effects of PEG length and iron oxide nanoparticles size on reduced protein adsorption and non-specific uptake by macrophage cells. J Nanosci Nanotechnol 2012;12:2094-100.

15. Ahmad T, Bae H, Rhee I, Chang Y, Lee J, Hong S. Particle size dependence of relaxivity for silica-coated iron oxide nanoparticles. Curr Appl Phys 2012;12:969-74.

16. Wang C, Chen J, Talavage T, Irudayaraj J. Gold Nanorod/Fe3O4 Nanoparticle “Nano‐Pearl‐Necklaces” for Simultaneous Targeting, Dual‐Mode Imaging, and Photothermal Ablation of Cancer Cells. Angew Chem 2009;121:2797-801.

17. LaConte LE, Nitin N, Zurkiya O, Caruntu D, O'Connor CJ, Hu X, et al. Coating thickness of magnetic iron oxide nanoparticles affects R2 relaxivity. J Magn Reson Imaging 2007;26:1634-41.

18. Tromsdorf UI, Bigall NC, Kaul MG, Bruns OT, Nikolic MS, Mollwitz B, et al. Size and surface effects on the MRI relaxivity of manganese ferrite nanoparticle contrast agents. Nano Lett 2007;7:2422-7.

19. Duan H, Kuang M, Wang X, Wang YA, Mao H, Nie S. Reexamining the effects of particle size and surface chemistry on the magnetic properties of iron oxide nanocrystals: new insights into spin disorder and proton relaxivity. J Phys Chem C 2008;112:8127-31.

20. Thanh NT. Magnetic nanoparticles: from fabrication to clinical applications: CRC press; 2012.

21. Khameneh B, Halimi V, Jaafari MR, Golmohammadzadeh S. Safranal-loaded solid lipid nanoparticles: evaluation of sunscreen and moisturizing potential for topical applications. Iran J Basic Med Sci 2015;18:58-63.

22. Lahooti A, Shanehsazzadeh S, Oghabian M A, Allen BJ. In Assessment of human effective absorbed dose of Tc-99m-USPIO based on biodistribution rat data. J Label Compd Rad 2013; S258-S258.

23. Jahanbakhsh R, Atyabi F, Shanehsazzadeh S, Sobhani Z, Adeli M, Dinarvand R. Modified Gadonanotubes as a promising novel MRI contrasting agent. Daru 2013;21:53-61.

24. Omid H, Oghabian MA, Ahmadi R, Shahbazi N, Hosseini HRM, Shanehsazzadeh S, et al. Synthesizing and staining manganese oxide nanoparticles for cytotoxicity and cellular uptake investigation. BBA-Gen Subjects 2014;1840:428-33.

25. Müller-Bierl B, Louis O, Fierens Y, Buls N, Luypaert R, de Mey J. Cylinders or walls? A new computational model to estimate the MR transverse relaxation rate dependence on trabecular bone architecture. Magn Reson Mater Phys Biol Med 2014;27:349-61.

26. Galassi F, Brujic D, Rea M, Lambert N, Desouza N, Ristic M. Fast and accurate localization of multiple RF markers for tracking in MRI-guided interventions. Magn Reson Mater Phys Biol Med 2015;28:33-48.

27. Marshall I, Jansen MA, Tao Y, Merrifield GD, Gray GA. Application of kt-BLAST acceleration to reduce cardiac MR imaging time in healthy and infarcted mice. Magn Reson Mater Phys Biol Med 2014;27:201-10.

28. Wang Y-XJ, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001;11:2319-31.